Central antinociception induced by µ‐opioid receptor agonist morphine, but not δ‐ or κ‐, is mediated by cannabinoid CB1 receptor
- 25 August 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (1), 225-231
- https://doi.org/10.1111/j.1476-5381.2009.00310.x
Abstract
It has been demonstrated that cannabinoids evoke the release of endogenous opioids to produce antinociception; however, no information exists regarding the participation of cannabinoids in the antinociceptive mechanisms of opioids. The aim of the present study was to determine whether endocannabinoids are involved in central antinociception induced by activation of mu-, delta- and kappa-opioid receptors. Nociceptive threshold to thermal stimulation was measured according to the tail-flick test in Swiss mice. Morphine (5 microg), SNC80 (4 microg), bremazocine (4 microg), AM251 (2 and 4 microg), AM630 (2 and 4 microg) and MAFP (0.1 and 0.4 microg) were administered by the intracerebroventricular route. The CB(1)-selective cannabinoid receptor antagonist AM251 completely reversed the central antinociception induced by morphine in a dose-dependent manner. In contrast, the CB(2)-selective cannabinoid receptor antagonist AM630 did not antagonize this effect. Additionally, the administration of the anandamide amidase inhibitor, MAFP, significantly enhanced the antinociception induced by morphine. In contrast, the antinociceptive effects of delta- and kappa-opioid receptor agonists were not affected by the cannabinoid antagonists. The antagonists alone caused no hyperalgesic or antinociceptive effects. The results provide evidence for the involvement of cannabinoid CB(1) receptors in the central antinociception induced by activation of mu-opioid receptors by the agonist morphine. The release of endocannabinoids appears not to be involved in central antinociception induced by activation of kappa- and delta-opioid receptors.This publication has 57 references indexed in Scilit:
- Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociceptionNeuropharmacology, 2008
- The μ‐opioid receptor agonist morphine, but not agonists at δ‐ or κ‐opioid receptors, induces peripheral antinociception mediated by cannabinoid receptorsBritish Journal of Pharmacology, 2008
- Endothelium‐dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2‐arachidonoylglycerolBritish Journal of Pharmacology, 2007
- In vivo neurochemical effects induced by changes in endocannabinoid neurotransmissionCurrent Opinion in Pharmacology, 2007
- Endocannabinoid mechanisms of pain modulationThe AAPS Journal, 2006
- μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesisBritish Journal of Pharmacology, 2006
- Modulation of Neuropathic and Inflammatory Pain by the Endocannabinoid Transport Inhibitor AM404 [N-(4-Hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]The Journal of pharmacology and experimental therapeutics, 2006
- Identification and Functional Characterization of Brainstem Cannabinoid CB 2 ReceptorsScience, 2005
- Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptorsLife Sciences, 1997
- Opioid receptor-coupled second messenger systemsLife Sciences, 1991